Wait-and-see treatment for people with rectal cancer
Part of Cancer, Digestive system clinical trials.
This study tests a “wait-and-see” approach instead of immediate surgery for certain rectal cancers, aiming to avoid unnecessary operations. It may help people who are medically able to stay under close monitoring and only have surgery if needed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older
- Your rectal cancer was seen on pelvic MRI as a specific stage pattern (like deeper spread into nearby tissue or lymph node involvement, but not simple T1N0 without high-risk features)
- You do not have known cancer spread to distant organs on CT scans of the chest and abdomen
- You are well enough for cancer surgery (good overall health rating) and can take oral study medicine
- Your blood counts and organ tests meet limits (enough white cells and platelets; acceptable liver, kidney, and bilirubin levels)
- You have no prior pelvic radiation and no major bowel problems that prevent safe oral treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a shorter course of radiation to the pelvis to treat rectal cancer, with the goal of avoiding surgery and preserving the rectum. It may be an option for people with advanced rectal cancer that has not spread to other organs.
This study tests a combination of internal radiation therapy (brachytherapy) followed by an immunotherapy drug (nivolumab) before surgery for rectal cancer. The goal is to see if this approach can shrink the tumor more and improve outcomes.
This trial looks at a “non-surgery” approach for some people with locally advanced rectal cancer who respond very well to radiation plus chemotherapy. If your cancer shows a complete clinical response on follow-up checks, the study may help you avoid an immediate major operation while closely monitoring you.
This study tests a new combination of treatment before surgery for high-risk rectal cancer. It combines a shorter course of radiation with chemotherapy and immunotherapy (which helps your immune system fight cancer) to see if it shrinks the tumor and improves outcomes.
This trial studies people with early-to-mid stage distal rectal cancer who may get radiation and chemotherapy, with an option that may include an extra drug (oxaliplatin). It also tests whether some people can safely follow a “watch and wait” plan instead of immediate additional treatment, aiming to reduce overtreatment while keeping cancer control.
This study looks at giving radiation and/or chemotherapy before surgery for rectal cancer that has come back in the pelvis. The goal is to see if this approach can shrink the tumor and make it easier to remove, potentially improving outcomes.
Hear when a new Colorectal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.